Libson, Karissa
Mehta, Nina
Kirven, Rachel
Korman, Abraham M.
Kaffenberger, Benjamin H.
Article History
Received: 22 January 2024
Revised: 22 January 2024
Accepted: 26 April 2024
First Online: 15 June 2024
Declarations
:
: Not required, as this is a secondary analysis of existing deidentified data.
: Not applicable.
: Dr. Benjamin Kaffenberger is an investigator for BMS, Biogen, Merck, InflaRx, OnQuality Pharmaceuticals, and the Dermatology Foundation and has consulted for Biogen, Onquality, Novocure, Novartis, and Elsevier.
: Dr. Benjamin Kaffenberger is an investigator for BMS, Biogen, Merck, InflaRx, OnQuality Pharmaceuticals, and the Dermatology Foundation and has consulted for Biogen, Onquality, Novocure, Novartis, and Elsevier.